New partners join the OMA consortium

Published on

The OMA network is delighted to welcome two new adjunct partners in the consortium.

 

OncoRay in Dresden, Germany, is a center for radiation research in oncology, with research focusing on the fields of medicine, physics, biology and information sciences. Its objective is to achieve a decisive improvement in the treatment of cancer using biologically individualized, technologically optimized radiotherapy. Key research projects include further development of image-guided proton therapy and the development of novel imaging-based monitoring procedures to accurately track the proton beam in the patient during treatment. The OncoRay partners are also working on a laser-based proton therapy. Further priorities at the Center lie in patient-oriented clinical research and the study of biomarkers for radiotherapy.

 

The University of Pennsylvania School of Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. The Department of Radiation Oncology at Penn Medicine is one of the largest and most respected programs in the world. The comprehensive program provides patients access to nearly every option available to treat their cancer. The broad range of radiation treatments available include proton therapy, intensity-modulated radiation therapy (IMRT), high-dose rate (HDR) and low-dose rate brachytherapy, partial breast irradiation, stereotactic radiosurgery (SRS) and Gamma Knife radiation. The department has an outstanding research program that provides patients with access to clinical trials that expand their treatment options.

 

Welcome to the OMA network!